Onset of action for loratadine tablets for the symptomatic control of seasonal allergic rhinitis in adults challenged with ragweed pollen in the Environmental Exposure Unit: a post hoc analysis of total symptom score
Abstract Background Loratadine is a second-generation, non-sedating antihistamine used for the relief of allergic rhinitis symptoms. Previous studies reported that when loratadine was encapsulated, the onset of action for symptom relief was 180 min. However, unmodified loratadine tablets were not ev...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-01-01
|
Series: | Allergy, Asthma & Clinical Immunology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13223-017-0227-4 |
id |
doaj-a2b4b1d0672241e8aa53b7b055a71f58 |
---|---|
record_format |
Article |
spelling |
doaj-a2b4b1d0672241e8aa53b7b055a71f582020-11-24T23:39:04ZengBMCAllergy, Asthma & Clinical Immunology1710-14922018-01-011411710.1186/s13223-017-0227-4Onset of action for loratadine tablets for the symptomatic control of seasonal allergic rhinitis in adults challenged with ragweed pollen in the Environmental Exposure Unit: a post hoc analysis of total symptom scoreMark W. Tenn0Lisa M. Steacy1Charlene C. Ng2Anne K. Ellis3Department of Biomedical and Molecular Sciences, Queen’s UniversityAllergy Research Unit, Kingston General HospitalBayer U.S. LLCDepartment of Biomedical and Molecular Sciences, Queen’s UniversityAbstract Background Loratadine is a second-generation, non-sedating antihistamine used for the relief of allergic rhinitis symptoms. Previous studies reported that when loratadine was encapsulated, the onset of action for symptom relief was 180 min. However, unmodified loratadine tablets were not evaluated at that time. Using data from a previously published Environmental Exposure Unit (EEU) study comparing azelastine nasal spray with loratadine tablets, cetirizine tablets, and placebo, this post hoc analysis determines the onset of action of loratadine tablets (i.e. unmodified) by analyzing the total symptom score for the relief of nasal and ocular seasonal allergic rhinitis (SAR) symptoms. Methods A Phase IV, randomized, single-center, double-blind, placebo-controlled, double-dummy, four-way crossover study was conducted in the EEU. Seventy participants were randomized sequentially into one of the four treatments during ragweed pollen exposure. Nasal and ocular symptom scores were self-reported by the participants and recorded. The original study analysis was carried out by evaluating the nasal symptom scores only. For this post hoc analysis, both nasal and ocular data from the loratadine and placebo treatment arms were analyzed. The primary endpoint for this analysis was the onset of action of loratadine as measured by the change in total symptom score (TSS) from baseline in comparison to placebo. The onset of ocular symptom relief using the total ocular symptom score (TOSS) was also reported. Results Loratadine tablets demonstrated a significant and durable improvement in both TSS (P = .005) and TOSS (P = .013) at 75 min post-treatment administration compared to placebo. The mean proportion of participants reporting none or mild for all component symptoms of TSS and TOSS at 75 min and thereafter was significantly higher in the loratadine (TSS, P = .0005; TOSS, P ≤ .0001) vs. placebo treatment arm. Conclusions The onset of action of loratadine tablets was 75 min for the relief of nasal and ocular symptoms in adults with SAR. These results suggest a faster onset of action for loratadine tablets (75 min) compared to previously reported studies which were conducted with modified (i.e. gelatin-encapsulated) loratadine tablets (180 min). Trial registration Clinicaltrials.gov identifier NCT00561717http://link.springer.com/article/10.1186/s13223-017-0227-4Allergic rhinitisEnvironmental Exposure UnitLoratadineOnset of actionRagweed pollenSeasonal allergies |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Mark W. Tenn Lisa M. Steacy Charlene C. Ng Anne K. Ellis |
spellingShingle |
Mark W. Tenn Lisa M. Steacy Charlene C. Ng Anne K. Ellis Onset of action for loratadine tablets for the symptomatic control of seasonal allergic rhinitis in adults challenged with ragweed pollen in the Environmental Exposure Unit: a post hoc analysis of total symptom score Allergy, Asthma & Clinical Immunology Allergic rhinitis Environmental Exposure Unit Loratadine Onset of action Ragweed pollen Seasonal allergies |
author_facet |
Mark W. Tenn Lisa M. Steacy Charlene C. Ng Anne K. Ellis |
author_sort |
Mark W. Tenn |
title |
Onset of action for loratadine tablets for the symptomatic control of seasonal allergic rhinitis in adults challenged with ragweed pollen in the Environmental Exposure Unit: a post hoc analysis of total symptom score |
title_short |
Onset of action for loratadine tablets for the symptomatic control of seasonal allergic rhinitis in adults challenged with ragweed pollen in the Environmental Exposure Unit: a post hoc analysis of total symptom score |
title_full |
Onset of action for loratadine tablets for the symptomatic control of seasonal allergic rhinitis in adults challenged with ragweed pollen in the Environmental Exposure Unit: a post hoc analysis of total symptom score |
title_fullStr |
Onset of action for loratadine tablets for the symptomatic control of seasonal allergic rhinitis in adults challenged with ragweed pollen in the Environmental Exposure Unit: a post hoc analysis of total symptom score |
title_full_unstemmed |
Onset of action for loratadine tablets for the symptomatic control of seasonal allergic rhinitis in adults challenged with ragweed pollen in the Environmental Exposure Unit: a post hoc analysis of total symptom score |
title_sort |
onset of action for loratadine tablets for the symptomatic control of seasonal allergic rhinitis in adults challenged with ragweed pollen in the environmental exposure unit: a post hoc analysis of total symptom score |
publisher |
BMC |
series |
Allergy, Asthma & Clinical Immunology |
issn |
1710-1492 |
publishDate |
2018-01-01 |
description |
Abstract Background Loratadine is a second-generation, non-sedating antihistamine used for the relief of allergic rhinitis symptoms. Previous studies reported that when loratadine was encapsulated, the onset of action for symptom relief was 180 min. However, unmodified loratadine tablets were not evaluated at that time. Using data from a previously published Environmental Exposure Unit (EEU) study comparing azelastine nasal spray with loratadine tablets, cetirizine tablets, and placebo, this post hoc analysis determines the onset of action of loratadine tablets (i.e. unmodified) by analyzing the total symptom score for the relief of nasal and ocular seasonal allergic rhinitis (SAR) symptoms. Methods A Phase IV, randomized, single-center, double-blind, placebo-controlled, double-dummy, four-way crossover study was conducted in the EEU. Seventy participants were randomized sequentially into one of the four treatments during ragweed pollen exposure. Nasal and ocular symptom scores were self-reported by the participants and recorded. The original study analysis was carried out by evaluating the nasal symptom scores only. For this post hoc analysis, both nasal and ocular data from the loratadine and placebo treatment arms were analyzed. The primary endpoint for this analysis was the onset of action of loratadine as measured by the change in total symptom score (TSS) from baseline in comparison to placebo. The onset of ocular symptom relief using the total ocular symptom score (TOSS) was also reported. Results Loratadine tablets demonstrated a significant and durable improvement in both TSS (P = .005) and TOSS (P = .013) at 75 min post-treatment administration compared to placebo. The mean proportion of participants reporting none or mild for all component symptoms of TSS and TOSS at 75 min and thereafter was significantly higher in the loratadine (TSS, P = .0005; TOSS, P ≤ .0001) vs. placebo treatment arm. Conclusions The onset of action of loratadine tablets was 75 min for the relief of nasal and ocular symptoms in adults with SAR. These results suggest a faster onset of action for loratadine tablets (75 min) compared to previously reported studies which were conducted with modified (i.e. gelatin-encapsulated) loratadine tablets (180 min). Trial registration Clinicaltrials.gov identifier NCT00561717 |
topic |
Allergic rhinitis Environmental Exposure Unit Loratadine Onset of action Ragweed pollen Seasonal allergies |
url |
http://link.springer.com/article/10.1186/s13223-017-0227-4 |
work_keys_str_mv |
AT markwtenn onsetofactionforloratadinetabletsforthesymptomaticcontrolofseasonalallergicrhinitisinadultschallengedwithragweedpollenintheenvironmentalexposureunitaposthocanalysisoftotalsymptomscore AT lisamsteacy onsetofactionforloratadinetabletsforthesymptomaticcontrolofseasonalallergicrhinitisinadultschallengedwithragweedpollenintheenvironmentalexposureunitaposthocanalysisoftotalsymptomscore AT charlenecng onsetofactionforloratadinetabletsforthesymptomaticcontrolofseasonalallergicrhinitisinadultschallengedwithragweedpollenintheenvironmentalexposureunitaposthocanalysisoftotalsymptomscore AT annekellis onsetofactionforloratadinetabletsforthesymptomaticcontrolofseasonalallergicrhinitisinadultschallengedwithragweedpollenintheenvironmentalexposureunitaposthocanalysisoftotalsymptomscore |
_version_ |
1725514777534398464 |